AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, June 5th at 12:00 PM ET
AIM Immunotech首席执行官Tom Equels将于美国东部时间6月5日星期三下午12:00进行直播视频网络研讨会。
OCALA, Fla., June 03, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series on Wednesday, June 5, 2024 at 12:00 PM ET.
佛罗里达州OCALA，2024年6月3日——AIM Immunotech股份有限公司。（纽约证券交易所美国：AIM）（“AIM”或“公司”）今天宣布Thomas K. Equels，MS JD，首席执行官AIM将于2024年6月5日星期三参加虚拟投资者午餐会客户系列活动。东部时间下午12点。
As part of the event, Mr. Equels will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Equels will answer as many questions as possible in the time allowed.
作为该活动的一部分，Equels先生将提供公司概述和业务前景。除了准备好的讲话外，感兴趣的各方还将有机会在活动期间实时提交问题。Equels先生将在允许的时间内回答尽可能多的问题。
A live video webcast of the presentation will be available on the Events page of the Company's website (aimimmuno.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
机器人演示的网络直播视频将在公司网站（aimimmuno.com）的“活动”页面上提供。演示的网络直播视频将在现场演示后两小时提供，并可访问90天。有关AIM Immunotech股份有限公司的信息，请访问aimimmuno.com并与公司联系。(aimimmuno.com)。演讲的网络直播视频将在现场演示后两小时提供，并可访问90天。
About AIM ImmunoTech Inc.
AIM Immunotech股份有限公司是一家免疫药品公司，专注于研究和开发治疗多种癌症、免疫性疾病和病毒性疾病（包括COVID-19）的治疗药物。该公司的主要产品是一种名为Ampligen（吡咯烷寡核苷酸）的首创调节免疫器官的药物，具有广泛的临床试验、覆盖全球重要癌症、病毒性疾病和免疫系统疾病的广谱活性。
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM Immunotech公司是一家免疫药物公司，专注于研究和开发治疗多种癌症、免疫失调和病毒性疾病（包括COVID-19）的治疗药物。该公司的主要产品是一种名为Ampligen（Rintatolimod）的首创性调节免疫药物，是一种dsRNA和高选择性TLR3激动剂，广泛应用于针对全球重要癌症、病毒性疾病和免疫系统疾病的临床试验中。
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
有关更多信息，请访问 aimimmuno.com并联系该公司。X, LinkedIn和Facebook.
Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
投资者联系人：JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com。
